NY-ESTÉE-LAUDER
19.11.2021 00:40:08 CET | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that Mark Loomis , currently President, Asia/Pacific, will be appointed President, North America , effective February 1, 2022. Mark will report directly to Fabrizio Freda, President and Chief Executive Officer, and he will remain a member of ELC’s Executive Leadership Team. An announcement regarding Asia/Pacific leadership will follow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006408/en/
“We are thrilled that Mark will take on leadership of our home market in North America,” said Fabrizio Freda , President and Chief Executive Officer . “Mark has successfully built and led high-performance organizations throughout his 25 years at The Estée Lauder Companies, delivering incredible results through his visionary strategic leadership and collaborative style. I look forward to our continued close partnership as Mark leads our talented North America team to build on their successes as the region continues to gain momentum.”
As President, North America, Mark’s responsibilities will include guiding the North America Leadership Team to help maximize sales, profitability, and market share growth in the company’s dynamic and fast-evolving home market. He will build on the region’s many successes, leveraging his commercial expertise to help drive the business strategy, fuel the recovery, and unlock opportunities across brands, consumers, and channels.
Mark will have accountability for top- and bottom-line results in the U.S. and Canada across brands and channels. Working closely with the North America Leadership Team, he will drive ELC’s continued transformation as a digital-first organization fueled by Online. He will leverage the company’s strong retailer relationships to help optimize productivity and create exceptional omni-experiences for consumers.
Mark will partner closely with ELC’s Group and Brand Presidents and Function leaders on innovation pipeline sufficiency, elevated brand equity-building, and resource allocation to the largest growth opportunities. He will nurture the region’s organizational culture to enable brands to execute their strategies with the greatest support, focus, speed, and agility, while also driving greater integration and best practices across the portfolio.
Mark has had an exemplary 25-year career with ELC, much of it spent in Asia, with deep global leadership experience spanning the company’s brands, channels, regions, and affiliates. In these roles, he has delivered exceptional results, successfully leading strategically significant beauty markets, including ELC’s businesses in Canada and Japan.
As President, Asia/Pacific, since 2018, Mark has led the region to extraordinary new heights through regional strategies that support business acceleration and commercial operations to drive growth across all 13 Asia/Pacific affiliates. His tenacity in identifying and driving key business opportunities helped to grow net sales for Asia/Pacific significantly and double the region’s Online business between fiscal 2019 and 2021.
Mark was instrumental to the company’s multi-year transformation initiative focused on elevating and growing the company’s business in the Asia/Pacific region and winning with the Chinese consumer domestically and abroad. He has partnered closely with Joy Fan , newly appointed President and CEO, China, as well as the Travel Retail team, in one of the most competitive and dynamic prestige beauty markets in the world. He has also been central to the development of enterprise-wide initiatives to serve consumers with speed, innovation, and local-relevance, including the company’s investment in the first-ever manufacturing facility in Japan, the expansion of ELC’s innovation capabilities through its new China Innovation Center in Shanghai, as well as the acquisition of Dr.Jart+ and Do The Right Thing in 2019.
“Throughout his tenure, Mark has demonstrated an unwavering commitment to business success, while also commanding the deep respect of everyone with whom he engages and cultivating a strong sense of ambition, belonging, and pride across the company,” said William P. Lauder, Executive Chairman . “Mark’s inspiring leadership abilities, strong strategic vision, and focus on business performance and results are matched only by his commitment to our teams, making him well suited to take on this role at the helm of ELC’s home market in North America.”
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may address our expectations regarding sales, earnings or other future financial performance and liquidity, other performance measures, product introductions, entry into new geographic regions, information technology initiatives, new methods of sale, our long-term strategy, restructuring and other charges and resulting cost savings, and future operations or operating results. Factors that could cause actual results to differ materially from our forward-looking statements are described in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2021. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc.
is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006408/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
